Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 14 May 2019, 09:12 HKT/SGT
Share:
    

Source: NEC Corporation
NEC Becomes the First Japanese Company to Join the TESLA Consortium's Fight Against Cancer

TOKYO, May 14, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the best algorithms to predict which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

Individualized neoantigen vaccines, which are tailored to each patient's tumor, are one of most advanced cancer treatments to show great promise for activating the immune system to fight cancer whilst reducing the chances of autoimmune responses.

NEC was accepted into the TESLA consortium given the uniqueness of the company's Neoantigen Prediction System. The prediction system utilizes NEC's cutting-edge AI technology, "NEC the WISE"(1), to identify and prioritize patient-specific neoantigens. NEC comprehensively evaluates candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

"By participating in this consortium, NEC will be able to collaborate with the world's leading research organizations and potentially improve the chances of survival for cancer patients with this new treatment option," said Osamu Fujikawa, Senior Vice President, NEC Corporation. "NEC focuses on the provision of social solutions and continues efforts to strengthen its next-generation healthtech businesses," he added.

(1) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.


Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511


Topic: Press release summary
Source: NEC Corporation

Sectors: Cloud & Enterprise, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Dec 19, 2024 11:02 HKT/SGT
NEC Completes new Asia Pacific submarine cable
Dec 18, 2024 16:12 HKT/SGT
NEC Receives Telecom Review's Global Excellence Award for Innovative Telecom B2B/ Enterprise Network Solutions
Dec 12, 2024 15:27 HKT/SGT
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024
Dec 9, 2024 13:06 HKT/SGT
NEC begins sale of 100G QSFP28 ZR4 single-fiber bi-directional optical transceiver
Nov 29, 2024 14:27 HKT/SGT
JAL and NEC Test AI-Powered Carry-On Baggage Analysis Solution
Nov 20, 2024 14:30 HKT/SGT
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 18, 2024 16:29 HKT/SGT
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 13, 2024 11:05 HKT/SGT
Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program
Nov 13, 2024 10:16 HKT/SGT
NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science
Nov 12, 2024 18:25 HKT/SGT
NEC participates in COP29 climate change conference
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: